Skip to content

Study · Animal study (in vivo) · rat · 2003

3 results

CNS melanocortin and leptin effects on stearoyl-CoA desaturase-1 and resistin expression.

Lin J, Choi YH, Hartzell DL, Li C, Della-Fera MA, Baile CA

Biochemical and biophysical research communications1 Nov 2003Cited by 35 (Europe PMC)

PMID14592417 (opens in a new tab)DOI10.1016/j.bbrc.2003.10.004 (opens in a new tab)PepBankPUB-14592417
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, intracerebroventricular MTII reduced stearoyl-CoA desaturase-1 (SCD1) expression.

    In plain wordsIn rats, MTII injected into the brain lowered SCD1 gene activity.

    Peptide
    Melanotan II
    Outcome
    DecreaseSCD1 expression in liver and adipose tissue
    Study

    ratn: not reported in source

    Comparator
    Artificial cerebrospinal fluid
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    0.1 nmol · intracerebroventricular · once daily for 4 daysAs given in this study (rat).

    Source sentences

    Summary
    Both leptin and MTII reduced SCD1 expression
    1 context sentence
    Summary · context
    Male Sprague-Dawley rats were injected into the lateral cerebral ventricle (i.c.v.) once daily for 4 days with artificial cerebrospinal fluid (aCSF, 5 microl), leptin (10 microg) or MTII (0.1 nmol); two other groups were pretreated icv with the melanocortin antagonist, SHU9119 (1.0 nmol), followed by leptin or MTII.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, intracerebroventricular MTII did not affect adipose resistin expression.

    In plain wordsIn rats, MTII injected into the brain did not change resistin gene activity.

    Peptide
    Melanotan II
    Outcome
    No significant changeAdipose resistin expression
    Study

    ratn: not reported in source

    Comparator
    Artificial cerebrospinal fluid
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    0.1 nmol · intracerebroventricular · once daily for 4 daysAs given in this study (rat).

    Source sentences

    Summary
    Neither leptin nor MTII affected resistin expression
    1 context sentence
    Summary · context
    Male Sprague-Dawley rats were injected into the lateral cerebral ventricle (i.c.v.) once daily for 4 days with artificial cerebrospinal fluid (aCSF, 5 microl), leptin (10 microg) or MTII (0.1 nmol); two other groups were pretreated icv with the melanocortin antagonist, SHU9119 (1.0 nmol), followed by leptin or MTII.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 03AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In rats, pretreatment with the melanocortin antagonist SHU9119 reversed the MTII-induced reduction in SCD1 expression.

    In plain wordsIn rats, the melanocortin blocker SHU9119 undid the lowering of SCD1 gene activity that MTII caused.

    Peptide
    Melanotan II
    Outcome
    IncreaseMTII-induced SCD1 reduction with SHU9119 pretreatment
    Study

    ratn: not reported in source

    Comparator
    Artificial cerebrospinal fluid
    Outcome group
    Receptor activity and mechanism · Metabolic and weight

    Source sentences

    Summary
    Both leptin and MTII reduced SCD1 expression and pretreatment with SHU9119 reversed their effects.
    1 context sentence
    Summary · context
    Male Sprague-Dawley rats were injected into the lateral cerebral ventricle (i.c.v.) once daily for 4 days with artificial cerebrospinal fluid (aCSF, 5 microl), leptin (10 microg) or MTII (0.1 nmol); two other groups were pretreated icv with the melanocortin antagonist, SHU9119 (1.0 nmol), followed by leptin or MTII.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.